Breast Lumps & Breast Cancer Pathways
Use concordant clinical, imaging and tissue assessment while distinguishing infection from persistent suspicious disease.
Quick revision ↓ Medical Dictionary
01Assess the presentation respectfully
Ask about duration, change, pain, nipple discharge, skin change, pregnancy or lactation, previous breast disease and family history. Examine both breasts and regional nodes with explanation, consent and an appropriate chaperone. A painful lump is not automatically benign and a young age does not eliminate risk. Document location and relevant findings so clinical and imaging teams are assessing the same lesion.
02Use triple assessment
Clinical examination, appropriate imaging and tissue sampling together form the basis of many breast-lump pathways. The imaging modality depends on age, pregnancy and local protocols. Core biopsy often provides architecture and biomarker information when malignancy is suspected. Concordance matters: a reassuring sample from the wrong or unrepresentative area should not override a persistent suspicious clinical or imaging finding.
03Recognise infection and abscess
Lactational mastitis and abscess require assessment of systemic illness and feeding circumstances, with appropriate antimicrobial and drainage plans. Ultrasound can identify a collection. Persistent inflammation, atypical features or failure to improve requires reassessment, including consideration of inflammatory malignancy. Do not repeatedly prescribe antibiotics without revisiting a lump or skin change that remains unexplained.
04Understand treatment planning
Confirmed cancer is assessed for extent, receptor status and patient fitness and preferences. Surgery, radiotherapy and systemic treatment can be combined in different sequences. Breast conservation and mastectomy are not selected from lump size alone; anatomy, tumour characteristics and patient priorities matter. Discuss axillary assessment, reconstruction and possible effects on function and body image through the multidisciplinary pathway.
05Support follow-up and survivorship
Communicate results clearly with a named contact and realistic timescale. Explain wound care and warning symptoms after procedures and address arm symptoms, lymphoedema risk, pain and psychosocial needs when relevant. Follow-up should include responsibility for pathology and treatment decisions. Patients with benign findings still need advice to return if the lesion changes or symptoms remain discordant with the assessment.
High-Yield Revision
- Triple assessment depends on agreement between its components.
- Pain or young age does not by itself exclude malignancy.
- Persistent inflammatory change requires reassessment.
Common Pitfalls
- Do not accept a benign sample when the overall assessment remains suspicious.
- Do not reduce breast treatment decisions to tumour size alone.
References & Further Reading
Read the relevant guideline sections alongside these original clinical teaching cases. Local pathways, available services and individual patient factors determine care.
Reference review: 27 September 2026. Consult current local protocols for prescribing, procedures and escalation.